For roughly four decades, oncologists had a grim shorthand for the most common genetic driver of pancreatic cancer: undruggable. The KRAS protein, mutated in about 90 percent of pancreatic tumors, resisted every small molecule researchers threw at it. That label started cracking in recent years with drugs targeting a single KRAS variant, G12C, but that mutation accounts for only a sliver of pancreatic cases. Now, results from a Phase 1/2 clinical trial published in the New England Journal of Medicine show that a broader-acting oral drug called daraxonrasib (RMC-6236) produced meaningful disease control in previously treated patients with RAS-mutated pancreatic cancer, a population that until recently had almost nowhere left to turn.
The findings have already prompted the FDA to grant daraxonrasib both Breakthrough Therapy and Orphan Drug designations and to authorize expanded access so patients outside the trial can receive the drug while formal review continues. For a disease that kills more than 50,000 Americans each year and carries a five-year survival rate of roughly 13 percent, those regulatory moves carry real weight.
What the trial found
The study, registered as NCT05379985, is an open-label, multicenter dose-escalation and expansion trial enrolling patients with advanced solid tumors driven by specific RAS mutations. The pancreatic cancer cohort is a prespecified expansion group, not an exploratory add-on, and the NEJM publication focuses on that cohort’s outcomes across four key endpoints: objective response rate, progression-free survival, overall survival, and duration of response.
What makes daraxonrasib different from earlier RAS-targeting drugs is its mechanism. Sotorasib and adagrasib, the first KRAS inhibitors to reach the market, lock onto a single mutation, KRAS G12C, which appears in only about 1 to 2 percent of pancreatic cancers. Daraxonrasib is a multi-RAS(ON) inhibitor, meaning it is designed to block several active-state RAS variants simultaneously. Because KRAS mutations are present in roughly 90 percent of pancreatic ductal adenocarcinomas, a drug that works across multiple variants could, in theory, reach a far larger share of patients than any single-mutation inhibitor.
The trial enrolled patients who had already been treated with prior chemotherapy, a population with limited options. Standard second-line regimens built around liposomal irinotecan have historically produced modest response rates and short-lived survival gains. Against that backdrop, the disease control reported with daraxonrasib caught the attention of both regulators and the oncology community. The NEJM paper details the specific response rates and survival figures; the peer-review process means independent experts evaluated the data and methodology before publication.
Why the FDA moved quickly
Breakthrough Therapy designation gives Revolution Medicines, the company developing daraxonrasib, more intensive FDA guidance and the possibility of a shorter review timeline. Orphan Drug designation provides development incentives for diseases affecting fewer than 200,000 Americans annually. But the step that stands out most is expanded access. By authorizing patients outside the trial to receive daraxonrasib before formal approval, the FDA signaled that the unmet need is severe enough to justify early availability, a judgment the agency does not make lightly.
Revolution Medicines disclosed related trial milestones and regulatory developments in its annual 10-K filing with the SEC for the fiscal year ended December 31, 2025, aligning its investor communications with the public regulatory record. The company has not yet announced a specific timeline for a potential approval application, and the FDA has not publicly detailed what additional data it will require. Breakthrough Therapy designation does not guarantee approval or a fixed schedule; it opens a faster lane, but the destination still depends on the strength of the evidence.
A second trial targets earlier-stage disease
A separate study, registered as NCT07252232, is already testing daraxonrasib in a very different setting: patients whose pancreatic tumors were surgically removed. In that adjuvant trial, the drug is being evaluated as a post-surgical therapy intended to reduce the risk of cancer returning after standard chemotherapy.
The rationale is straightforward but urgent. Even among the minority of pancreatic cancer patients who qualify for surgery and survive the operation, recurrence rates remain stubbornly high. If daraxonrasib can lower that risk, it would address one of the most frustrating realities in pancreatic cancer care. The trial is in its early stages, and mature recurrence-free survival data will take years to accumulate, but the decision to move into an adjuvant setting reflects confidence in the drug’s biological rationale.
What is still missing from the picture
Several important questions remain open. The specific response rates, median progression-free survival, and median overall survival figures for the pancreatic cohort are detailed in the full NEJM publication but have not been widely excerpted in public summaries. Without those numbers, direct comparisons to existing second-line chemotherapy regimens are difficult to make with precision.
Safety is another gap. The trial tracked grade 3 or higher adverse events and treatment discontinuations, but the detailed tolerability profile matters enormously for this patient population. People with advanced pancreatic cancer are often physically worn down by prior rounds of chemotherapy. A drug that shrinks tumors but causes severe side effects may offer limited benefit in practice. Clinicians considering expanded access will need granular toxicity data to counsel patients appropriately.
Then there is the durability problem. Pancreatic cancer is notorious for developing resistance to therapy quickly. Whether daraxonrasib’s disease control holds at 12 or 18 months will matter far more than early response rates. The same biology that made RAS difficult to target, including redundant signaling pathways that tumors can exploit, raises the possibility that resistance will emerge. Understanding which specific RAS alterations respond best, and how resistance develops, will be critical for deciding how to combine or sequence daraxonrasib with chemotherapy and other agents.
Finally, the path from expanded access to a marketed drug is not automatic. Accelerated approval based on early-phase data is possible, but the FDA often requires confirmatory randomized evidence, typically a Phase 3 trial comparing the drug directly against standard treatment in a larger, more diverse population. Whether daraxonrasib will be judged against historical controls or head-to-head against chemotherapy has not been publicly disclosed.
Where this fits in the RAS-targeting revolution
Daraxonrasib did not emerge in a vacuum. The past five years have seen a wave of progress against RAS-driven cancers after decades of failure. Sotorasib received FDA approval in 2021 for KRAS G12C-mutated non-small cell lung cancer. Adagrasib followed. But those drugs address a narrow slice of RAS biology. Daraxonrasib’s multi-RAS approach represents the next logical step: rather than picking off one mutation at a time, it attempts to block the protein in its active state across several variants.
For pancreatic cancer specifically, this broader targeting matters because KRAS G12D and G12V, not G12C, are the dominant mutations. A drug that works only on G12C would miss the vast majority of patients. Daraxonrasib’s design is aimed squarely at that gap, and the Phase 1/2 results suggest the approach is producing clinical benefit, not just laboratory activity.
Still, cautious optimism is the appropriate posture. The evidence as of June 2026 supports the idea that daraxonrasib can shrink or stabilize tumors in a subset of people with heavily pretreated, RAS-mutated pancreatic cancer, and that U.S. regulators see enough promise to justify expanded access before formal approval. But critical data on long-term survival, real-world tolerability, and durability of response are still maturing. Until randomized trials confirm a clear advantage over current standards, daraxonrasib remains a compelling investigational option, not yet a proven new standard of care. For a disease where genuine progress has been agonizingly slow, that distinction matters, but so does the fact that progress is finally happening.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
